Compounds of the formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein, R.sup.1 is optionally substituted pyrazolyl, and R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X.sub.3 and/or a P2X.sub.2/3 receptor antagonists and methods of making the compounds.

Provided are compounds represented by the formula: with Y, Ri, and R2 being defined in the present disclosure; pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition capable of treatment with a partial agonist or antagonist of the dopamine D2/D3 receptors and are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as Parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders. Also provided are processes for the preparation of compounds of the present disclosure. ##STR00001##

The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is ##STR00001##
or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.

The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is ##STR00001##
or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.